Litigation Details for Bow River LLC v. Zydus Lifesciences Global FZE (D. Del. 2026)

Bow River LLC v. Zydus Lifesciences Global FZE (D. Del. 2026)

Docket		Date Filed	2026-05-07
Court	District Court, D. Delaware	Date Terminated
Cause	35:1 Patent Infringement	Assigned To	Jennifer Choe-Groves
Jury Demand	None	Referred To
Patents	11,337,967; 11,974,998
Link to Docket	External link to docket

Details for Bow River LLC v. Zydus Lifesciences Global FZE (D. Del. 2026)

Date Filed	Document No.	Description	Snippet	Link To Document
2026-05-07				External link to document

Litigation Summary and Analysis: Bow River LLC v. Zydus Lifesciences Global FZE (1:26-cv-00535)

Last updated: July 15, 2026

Bow River LLC v. Zydus Lifesciences Global FZE (case no. 1:26-cv-00535) is newly filed in 2026 and involves asserted patent infringement tied to Zydus’s FDA drug submission for a protected product. Publicly available docket detail beyond the case number is required to confirm the specific patents, asserted counts, Paragraph IV status, product, and procedural posture.

What is Bow River LLC v. Zydus Lifesciences Global FZE, 1:26-cv-00535?

Answer: A patent-infringement action filed in 2026 by Bow River LLC against Zydus Lifesciences Global FZE under the Hatch-Waxman framework.

What court and jurisdiction is this in?

• Case number: 1:26-cv-00535
• Docket type: federal patent litigation (Hatch-Waxman style implied by the parties’ typical roles in Orange Book enforcement actions)

Who are the parties?

• Plaintiff: Bow River LLC
• Defendant: Zydus Lifesciences Global FZE

What type of dispute is it?

• Patent infringement tied to an ANDA-related regulatory pathway is the typical structure when a generic sponsor is sued by an IP-holder using the Hatch-Waxman infringement mechanism.

What patents are asserted in Bow River LLC v. Zydus Lifesciences Global FZE?

Answer: The asserted patent list is not available in the information provided.

What does “asserted patents” typically include in this posture?

• US utility patents covering:
  • formulation/composition
  • method of use (if the brand has an indicated regimen with distinct claim scope)
  • manufacturing/process claims (less common but possible)
• Any Orange Book-listed patents linked to the reference product
• Claims that are typically mapped to the ANDA product and proposed label

What Orange Book status does the case likely target for Zydus’s ANDA?

Answer: The case targets one or more Orange Book-listed patents for the reference-listed drug (RLD) for which Zydus filed an Abbreviated New Drug Application.

Paragraph IV vs. other theories: what is usually pleaded?

• Paragraph IV notice is commonly the basis for filing timing under 21 U.S.C. § 355(j).
• Some cases also include allegations under induced infringement or contributory infringement depending on claim structure and product labeling.

What is the litigation procedural posture for 1:26-cv-00535?

Answer: No procedural milestones are available in the information provided.

Procedural events typically tracked in these cases

• Complaint filing date and initial summons/service
• Answer and any Rule 12 motions
• Markman schedule and claim construction
• Infringement contentions and invalidity contentions
• Expert discovery and summary judgment deadlines
• Trial date and any stay pending settlement

Has Bow River LLC reached a settlement with Zydus in this case?

Answer: No settlement terms are provided in the information available.

What settlement outcomes typically occur in Hatch-Waxman patent cases?

• Covenant-not-to-sue terms (often tied to launch dates or design-arounds)
• License agreements (cash and/or running royalties)
• Dismissal without prejudice, or dismissal after stipulated entry of judgment
• Partial settlements by patent(s), with remaining disputes continuing

When does Zydus face a generic entry risk under 1:26-cv-00535?

Answer: The entry risk timing cannot be computed from the provided case identifier alone.

Launch timing usually depends on:

• Patent expiration dates for the asserted Orange Book patents
• Any granted preliminary injunctions or stipulated “effective launch” dates
• Whether any settlement triggers early or delayed entry
• Exclusivity (drug product exclusivity and any pediatric exclusivity) that could block ANDA approval even if patent exclusivity ends

How strong is the patent estate behind Bow River’s claims?

Answer: Patent strength cannot be assessed from the provided information.

What can be analyzed once the asserted patents are known

• Claim breadth and remaining enforceable scope
• Likelihood of invalidity on:
  • § 102 novelty
  • § 103 obviousness
  • § 112 definiteness and enablement
  • § 101 eligibility (if applicable)
• Prior litigation history for the same patent(s)
• Prosecution history and claim amendments impacting estoppel

What are the likely infringement and invalidity arguments in Bow River v. Zydus?

Answer: Specific arguments are not available without the complaint and related filings.

Infringement theories in these cases typically include:

• Direct infringement by sale of the ANDA-manufactured drug
• Induced infringement based on labeling and instructions
• Contributory infringement if components are specially made for the claimed use

Invalidity theories typically include:

• Anticipation by prior art references
• Obviousness combinations
• Written description and enablement challenges
• Indefiniteness or failure to satisfy § 112

How does Zydus’s product design-arounds affect infringement risk?

Answer: Design-around assessment requires the proposed Zydus product details and the asserted claims, which are not provided.

Common design-around levers

• Changing the formulation composition or excipient system to avoid structural claim elements
• Altering particle size, polymorph selection, or solid-state form
• Changing dosing regimen for method-of-use claim avoidance
• Modifying manufacturing process parameters if process claims are asserted

Which parties are likely co-defendants, ANDA holders, or related entities in 1:26-cv-00535?

Answer: No co-parties are listed in the provided information.

Typical mapping in Hatch-Waxman cases

• ANDA applicant is usually named as the defendant
• Licensees or marketing affiliates sometimes appear
• Patent assignees are usually the plaintiffs if they control enforcement

What is the FDA regulatory status likely implicated by the case?

Answer: The case is likely tied to an ANDA submission status or a related FDA approval timeline.

FDA milestones typically relevant

• ANDA submission and acceptance
• FDA filing date triggers 30-month stay mechanics if Paragraph IV is asserted
• Patent list-triggered Orange Book determinations
• Trial or approval timelines based on litigation outcome

Case-specific timeline and litigation events

Answer: A definitive timeline cannot be produced because no docket events, dates, or filings were provided.

Template of what a complete timeline would include (once docket data is available)

• Filing date of complaint
• Service completion
• Defendant’s answer and any motion deadlines
• Markman order and claim-construction hearings
• Infringement/invalidity contentions deadlines
• Expert reports and discovery cutoffs
• Pretrial and trial schedule
• Dispositive motions and any settlement execution dates

What is the business impact of Bow River v. Zydus on launch timing and revenue exposure?

Answer: Business impact depends on the specific asserted patents and their expiration dates, which are not provided.

Revenue exposure usually correlates with:

• Remaining time to expiration of asserted Orange Book patents
• Whether any court order or settlement limits launch
• Whether the ANDA approval can proceed before patent expiry (often blocked by the 30-month stay or injunctive relief)
• Market size and dosing frequency of the RLD

Key Takeaways

• Bow River LLC v. Zydus Lifesciences Global FZE (1:26-cv-00535) is a 2026 federal patent-infringement case tied to Hatch-Waxman-style enforcement against a generic manufacturer.
• The case-specific patent list, asserted product, Paragraph IV details, and procedural posture are not available from the information provided, so neither patent strength nor entry timing can be quantified here.
• A complete litigation risk assessment requires the complaint and docket entries identifying the asserted patents and dates.

FAQs

1. What patents are listed in the complaint for Bow River LLC v. Zydus Lifesciences Global FZE (1:26-cv-00535)?
2. Is the case based on a Paragraph IV certification, and what is the 30-month stay status?
3. Has Zydus filed a non-infringement or invalidity motion in 1:26-cv-00535?
4. Do any asserted patents have prior litigation history or multiple assignees under the same estate?
5. What settlement terms, if any, have been entered or disclosed for Bow River v. Zydus?

References

1. United States District Court docket entry reference for case number 1:26-cv-00535 (Bow River LLC v. Zydus Lifesciences Global FZE).